Paper on Asthma Therapy Adherence and Persistence, Coauthored by Analysis Group Researchers, Recognized by the Journal of Allergy and Clinical Immunology: In Practice
October 19, 2023
A paper by Analysis Group Chief Epidemiologist and Managing Principal Mei Sheng Duh, Principal François Laliberté, and Managers Guillaume Germain and Sean MacKnight, along with coauthors from the University of Wisconsin School of Medicine and Public Health and GlaxoSmithKline, has been recognized by the Journal of Allergy and Clinical Immunology: In Practice as being one of the publication’s most downloaded articles of 2022. In “Adherence and Persistence to Single-Inhaler Versus Multiple-Inhaler Triple Therapy for Asthma Management,” the coauthors described a real-world retrospective cohort study that they conducted using a large nationwide claims database among US patients with asthma. The objective of the study was to compare medication adherence to and persistence in the use of the single-inhaler triple therapy of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI, i.e., Trelegy Ellipta™) versus multiple-inhaler triple therapy.
The coauthors found that initiation of FF/UMEC/VI in a single inhaler was associated with significantly higher adherence and persistence among asthma patients, as compared to treatments using multiple once- or twice-daily inhalation therapies. They indicated that further research is warranted to assess how improved adherence to and persistence in single-inhaler FF/UMEC/VI use may positively affect clinical and economic outcomes for patients with asthma. The study was funded by GlaxoSmithKline.
Analysis Group congratulates the coauthors on their accomplishments.